 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BI 1819479 / Boehringer Ingelheim
Trial completion: A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 (clinicaltrials.gov) - Aug 14, 2023
P1, N=62, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- || BI 1819479 / Boehringer Ingelheim
Trial completion, Trial completion date, Trial primary completion date: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated (clinicaltrials.gov) - Mar 23, 2023
P1, N=24, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2023 --> Dec 2022 | Trial primary completion date: Apr 2023 --> Dec 2022
- || BI 1819479 / Boehringer Ingelheim
Enrollment closed: A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 (clinicaltrials.gov) - Mar 10, 2023
P1, N=60, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial completion date: Apr 2023 --> Dec 2022 | Trial primary completion date: Apr 2023 --> Dec 2022 Recruiting --> Active, not recruiting
- || BI 1819479 / Boehringer Ingelheim
Trial completion: A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (clinicaltrials.gov) - Jan 26, 2023
P1, N=15, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || BI 1819479 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (clinicaltrials.gov) - Nov 15, 2022
P1, N=16, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || BI 1819479 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (clinicaltrials.gov) - Oct 20, 2022
P1, N=16, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || BI 1819479 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated (clinicaltrials.gov) - Aug 8, 2022
P1, N=24, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| BI 1819479 / Boehringer Ingelheim
Enrollment open: A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 (clinicaltrials.gov) - Jul 28, 2022
P1, N=60, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || BI 1819479 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated (clinicaltrials.gov) - Jul 23, 2022
P1, N=24, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 1819479 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (clinicaltrials.gov) - Jul 20, 2022
P1, N=16, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| BI 1819479 / Boehringer Ingelheim
New P1 trial: A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479 (clinicaltrials.gov) - Jul 1, 2022
P1, N=60, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| BI 1819479 / Boehringer Ingelheim
Trial completion: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food (clinicaltrials.gov) - May 3, 2022
P1, N=66, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || BI 1819479 / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food (clinicaltrials.gov) - Feb 16, 2022
P1, N=66, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || BI 1819479 / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food (clinicaltrials.gov) - Sep 23, 2021
P1, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
- ||| BI 1819479 / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food (clinicaltrials.gov) - Jun 3, 2021
P1, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022 Not yet recruiting --> Recruiting
- ||| BI 1819479 / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food (clinicaltrials.gov) - Mar 17, 2021
P1, N=68, Not yet recruiting, Sponsor: Boehringer Ingelheim